New Alzheimer’s Drugs: Effectiveness and Controversy Under Scrutiny

When the headlines started swirling around whether the latest Alzheimer’s drugs actually move the needle for patients—or just drain wallets and dash hopes—I wasn’t just reading as a journalist. I was thinking about my own aunt in Milwaukee, who’s been navigating mild cognitive impairment for the past three years, her neurologist appointments becoming as routine as her coffee order at Anodyne Coffee Roasters on Brady Street. The global debate over amyloid-targeting therapies—sparked by recent critiques from outlets like Medical Republic, the BBC, and The Guardian questioning whether drugs like lecanemab and donanemab offer anything beyond statistically significant but clinically meaningless change—hit different when you picture it playing out in the waiting rooms of Froedtert Hospital or the research corridors of the Medical College of Wisconsin. This isn’t abstract science. it’s a visceral, urgent conversation happening in living rooms from Wauwatosa to West Allis, where families are weighing promises of slowed decline against infusion schedules that eat up entire days and out-of-pocket costs that can rival a second mortgage.

Let’s ground this in what we actually know from the data, not the hype. The phase 3 trials for lecanemab showed a 27% slowing of cognitive decline over 18 months compared to placebo—a figure that sounds impressive until you realize it translates to roughly a six-month delay in symptom progression for someone in the early stages of Alzheimer’s. For donanemab, the numbers are similar: a bit over a 30% slowing in one key metric, but with nearly 37% of participants experiencing brain swelling or bleeding (ARIA), a serious side effect requiring frequent MRI monitoring. Now, layer on the cost: lecanemab runs about $26,500 annually before insurance, donanemab around $32,000. In Wisconsin, where Medicaid eligibility thresholds are strict and Medicare Part B covers only 80% of the drug cost after the deductible, patients could still face annual out-of-pocket bills exceeding $5,000—assuming they even qualify based on amyloid PET scan results, which aren’t always covered either. That’s a steep price for a chance to maybe remember your granddaughter’s name a little longer.

But the implications ripple far beyond the pharmacy counter. Consider the strain on Milwaukee’s already stretched elder care infrastructure. If even a fraction of the estimated 110,000 Wisconsin residents aged 65+ living with Alzheimer’s pursue these therapies, we’re looking at a surge in demand for infusion center capacity—spaces currently occupied by cancer patients needing chemotherapy or those receiving IVIG for autoimmune disorders. Froedtert’s Neuroscience Center, already operating near capacity, would need significant expansion or reallocation of resources. Then there’s the caregiver burden: monthly infusions mean frequent trips to clinics, often relying on family members to take time off work or navigate Milwaukee County Transit System routes that aren’t always reliable in winter. And let’s not overlook the psychological toll—false hope can be as damaging as no hope at all when families pour savings into treatments that deliver marginal benefit, delaying honest conversations about palliative care or quality-of-life focused planning.

Yet amid the skepticism, there’s nuance worth honoring. Researchers at the University of Wisconsin-Madison’s Alzheimer’s Disease Research Center (ADRC) emphasize that these drugs represent the first time we’ve modified the underlying biology of Alzheimer’s, not just treated symptoms. For some patients—particularly those with very early-stage disease and minimal tau burden—the slowing of decline might mean retaining independence long enough to attend a child’s graduation or take one last trip to Door County. The ADRC’s ongoing work, including the AHEAD study testing pre-symptomatic intervention, suggests we’re still in the foothills of understanding how to deploy these tools effectively. It’s not that the drugs are useless; it’s that we’ve yet to match the right therapy to the right patient at the right time—a challenge that demands better biomarkers, smarter trial designs, and honest conversations about what “meaningful difference” really means to a person, not just a statistical model.

Navigating the Crossroads: What Milwaukee Families Actually Need

Given my background in translating complex medical science into actionable community insight, if you or someone you love is grappling with whether these Alzheimer’s therapies make sense in the context of daily life here—whether you’re near the lakefront in Shorewood, raising kids in Wauwatosa, or managing aging parents’ care from a condo near the Fiserv Forum—here’s what matters most when seeking local support. Forget generic advice; focus on providers who understand the specific intersection of neurology, geriatric care, and the practical realities of living in southeastern Wisconsin.

First, look for Geriatric Neurology Specialists with Deep Alzheimer’s Expertise. These aren’t just any neurologists; they’re clinicians who spend significant time in memory disorders clinics, participate in research trials through institutions like the UW-Madison ADRC or the Clement J. Zablocki VA Medical Center’s Geriatric Research Education and Clinical Center (GRECC), and understand the nuanced criteria for amyloid-targeting therapies—including who is truly a candidate based on disease stage, comorbidities, and genetic risk factors like APOE status. They should be able to walk you through the full risk-benefit profile in plain language, discuss infusion logistics specific to Milwaukee-area centers (like those at Froedtert or Aurora Sinai), and assist interpret complex biomarker results without jargon. Crucially, they’ll also know when not to pursue these drugs—prioritizing symptom management, behavioral support, or enrollment in non-drug trials when the potential harms outweigh the uncertain benefits.

Second, seek out Dementia Care Navigators or Social Workers Focused on Insurance and Access. The financial and logistical maze surrounding these drugs is brutal. You need professionals who know Wisconsin Medicaid’s intricate waiver programs (like Family Care or IRIS), can help appeal prior authorizations with Medicare Advantage plans, and understand the landscape of patient assistance programs offered by Eisai and Lilly—including their actual eligibility thresholds and application timelines. Ideally, they’re embedded in community hubs like the Alzheimer’s Association Wisconsin Chapter’s Milwaukee office or work within large health systems’ patient advocacy departments, connecting families to respite care options through agencies like Interfaith Older Adult Programs or helping coordinate transportation via Milwaukee County’s Transit Plus service for those unable to drive.

Third, and perhaps most critically, find Holistic Brain Health Practitioners Emphasizing Lifestyle and Prevention. While the drugs grab headlines, the evidence for foundational lifestyle interventions—regular aerobic exercise (consider walking the Oak Leaf Trail or swimming at the UWM Pool), Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet adherence, cognitive stimulation through programs at Milwaukee Public Library branches, and robust social engagement—remains some of our most powerful tools against cognitive decline. Look for providers who integrate these elements: perhaps a neuropsychologist who also offers personalized exercise prescriptions via partnerships with local YMCAs, a registered dietitian specializing in neuroprotective nutrition who shops at the South Milwaukee Farmers Market, or a therapist facilitating mindfulness groups at Unity Lutheran Church in Wauwatosa. They understand that drugs, if used, should complement—not replace—a comprehensive brain health strategy rooted in daily habits that cost little but yield profound resilience over time.

Ready to find trusted professionals? Browse our complete directory of top-rated dementia care experts in the Milwaukee area today.